{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T22:44:32Z","timestamp":1789598672331,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T00:00:00Z","timestamp":1743292800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T00:00:00Z","timestamp":1743292800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"DOI":"10.1007\/s00330-025-11533-0","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T23:39:50Z","timestamp":1743464390000},"page":"6507-6515","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Concordance of vibration-controlled transient elastography and magnetic resonance elastography for fibrosis staging in patients with metabolic dysfunction-associated steatotic liver disease"],"prefix":"10.1007","volume":"35","author":[{"given":"Anandita","family":"Mathur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efe","family":"Ozkaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonam","family":"Rosberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith M.","family":"Sigel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Doucette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meena B.","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6409-1333","authenticated-orcid":false,"given":"Bachir","family":"Taouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,30]]},"reference":[{"key":"11533_CR1","doi-asserted-by":"crossref","unstructured":"Canivet CM, Boursier J (2022) Screening for liver fibrosis in the general population: Where do we stand in 2022? Diagnostics (Basel) 13:91","DOI":"10.3390\/diagnostics13010091"},{"key":"11533_CR2","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1097\/HEP.0000000000000604","volume":"79","author":"BP Lee","year":"2024","unstructured":"Lee BP, Dodge JL, Terrault NA (2024) National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature. Hepatology 79:666\u2013673","journal-title":"Hepatology"},{"key":"11533_CR3","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1097\/HEP.0000000000000670","volume":"79","author":"F Kanwal","year":"2024","unstructured":"Kanwal F, Neuschwander-Tetri BA, Loomba R, Rinella ME (2024) Metabolic dysfunction-associated steatotic liver disease: update and impact of new nomenclature on the American Association for the Study of liver diseases practice guidance on nonalcoholic fatty liver disease. Hepatology 79:1212\u20131219","journal-title":"Hepatology"},{"key":"11533_CR4","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","volume":"184","author":"R Loomba","year":"2021","unstructured":"Loomba R, Friedman SL, Shulman GI (2021) Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell 184:2537\u20132564","journal-title":"Cell"},{"key":"11533_CR5","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/hep.29085","volume":"65","author":"PS Dulai","year":"2017","unstructured":"Dulai PS, Singh S, Patel J et al (2017) Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology 65:1557\u20131565","journal-title":"Hepatology"},{"key":"11533_CR6","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","volume":"385","author":"AJ Sanyal","year":"2021","unstructured":"Sanyal AJ, Van Natta ML, Clark J et al (2021) Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N Engl J Med 385:1559\u20131569","journal-title":"N Engl J Med"},{"key":"11533_CR7","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","volume":"13","author":"S Singh","year":"2015","unstructured":"Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R (2015) Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 13:643","journal-title":"Clin Gastroenterol Hepatol"},{"key":"11533_CR8","doi-asserted-by":"publisher","first-page":"e222695","DOI":"10.1148\/radiol.222695","volume":"310","author":"D Kadi","year":"2024","unstructured":"Kadi D, Loomba R, Bashir MR (2024) Diagnosis and monitoring of nonalcoholic steatohepatitis: current state and future directions. Radiology 310:e222695","journal-title":"Radiology"},{"key":"11533_CR9","doi-asserted-by":"publisher","unstructured":"Chen VL, Morgan TR, Rotman Y et al (2024) Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD practice guidance. Hepatology. https:\/\/doi.org\/10.1097\/HEP.0000000000001112","DOI":"10.1097\/HEP.0000000000001112"},{"key":"11533_CR10","doi-asserted-by":"publisher","first-page":"155835","DOI":"10.1016\/j.metabol.2024.155835","volume":"154","author":"M Kokkorakis","year":"2024","unstructured":"Kokkorakis M, Boutari C, Hill MA et al (2024) Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: trials, opportunities, and challenges. Metabolism 154:155835.","journal-title":"Metabolism"},{"key":"11533_CR11","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, Bedossa P, Guy CD et al (2024) A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med 390:497\u2013509","journal-title":"N Engl J Med"},{"key":"11533_CR12","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1053\/j.gastro.2021.07.049","volume":"161","author":"F Kanwal","year":"2021","unstructured":"Kanwal F, Shubrook JH, Adams LA et al (2021) Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. Gastroenterology 161:1657\u20131669","journal-title":"Gastroenterology"},{"key":"11533_CR13","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS et al (2023) AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 77:1797\u20131835","journal-title":"Hepatology"},{"key":"11533_CR14","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1111\/apt.17953","volume":"59","author":"A De Vincentis","year":"2024","unstructured":"De Vincentis A, Tavaglione F, Namba S et al (2024) Poor accuracy and sustainability of the first-step FIB4 EASL pathway for stratifying steatotic liver disease risk in the general population. Aliment Pharm Ther 59:1402\u20131412","journal-title":"Aliment Pharm Ther"},{"key":"11533_CR15","doi-asserted-by":"publisher","unstructured":"Ogawa Y, Tomeno W, Imamura Y et al (2024) Distribution of fibrosis-4 index and vibration-controlled transient elastography-derived liver stiffness measurement for patients with metabolic dysfunction-associated steatotic liver disease in health check-up. Hepatol Res. https:\/\/doi.org\/10.1111\/hepr.14117","DOI":"10.1111\/hepr.14117"},{"key":"11533_CR16","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1097\/HEP.0000000000000852","volume":"81","author":"A Duarte-Rojo","year":"2024","unstructured":"Duarte-Rojo A, Taouli B, Leung DH et al (2024) Imaging-based non-invasive liver disease assessment for staging liver fibrosis in chronic liver disease: a systematic review supporting the AASLD Practice Guideline. Hepatology 81:725\u2013774. https:\/\/doi.org\/10.1097\/HEP.0000000000000852","journal-title":"Hepatology"},{"key":"11533_CR17","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.cgh.2018.05.059","volume":"17","author":"C Hsu","year":"2019","unstructured":"Hsu C, Caussy C, Imajo K et al (2019) Magnetic resonance vs transient elastography analysis of patients with nonalcoholic fatty liver disease: a systematic review and pooled analysis of individual participants. Clin Gastroenterol Hepatol 17:630","journal-title":"Clin Gastroenterol Hepatol"},{"key":"11533_CR18","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1053\/j.gastro.2015.11.048","volume":"150","author":"K Imajo","year":"2016","unstructured":"Imajo K, Kessoku T, Honda Y et al (2016) Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography. Gastroenterology 150:626\u2013637.e627","journal-title":"Gastroenterology"},{"key":"11533_CR19","doi-asserted-by":"publisher","first-page":"S70","DOI":"10.1016\/S0016-5085(17)30587-5","volume":"152","author":"CC Park","year":"2017","unstructured":"Park CC, Nguyen P, Hernandez C et al (2017) Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease. Gastroenterology 152:S70","journal-title":"Gastroenterology"},{"key":"11533_CR20","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1007\/s00261-022-03618-x","volume":"47","author":"HA Lee","year":"2022","unstructured":"Lee HA, Kim SS, Choi JY et al (2022) Magnetic resonance imaging improves stratification of fibrosis and steatosis in patients with chronic liver disease. Abdom Radiol (NY) 47:3733\u20133745","journal-title":"Abdom Radiol"},{"key":"11533_CR21","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.jhep.2016.06.005","volume":"65","author":"PS Dulai","year":"2016","unstructured":"Dulai PS, Sirlin CB, Loomba R (2016) MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: clinical trials to clinical practice. J Hepatol 65:1006\u20131016","journal-title":"J Hepatol"},{"key":"11533_CR22","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1007\/s00330-024-11001-1","volume":"35","author":"N Azizi","year":"2024","unstructured":"Azizi N, Naghibi H, Shakiba M et al (2024) Evaluation of MRI proton density fat fraction in hepatic steatosis: a systematic review and meta-analysis. Eur Radiol 35:1794\u20131807. https:\/\/doi.org\/10.1007\/s00330-024-11001-1","journal-title":"Eur Radiol"},{"key":"11533_CR23","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.jhep.2023.04.025","volume":"79","author":"JX Liang","year":"2023","unstructured":"Liang JX, Ampuero J, Niu H et al (2023) An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography. J Hepatol 79:592\u2013604","journal-title":"J Hepatol"},{"key":"11533_CR24","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1053\/j.gastro.2019.01.042","volume":"156","author":"PJ Eddowes","year":"2019","unstructured":"Eddowes PJ, Sasso M, Allison M et al (2019) Accuracy of fibroscan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 156:1717\u20131730","journal-title":"Gastroenterology"},{"key":"11533_CR25","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.jhep.2016.12.022","volume":"66","author":"T Karlas","year":"2017","unstructured":"Karlas T, Petroff D, Sasso M et al (2017) Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol 66:1022\u20131030","journal-title":"J Hepatol"},{"key":"11533_CR26","doi-asserted-by":"publisher","first-page":"e220181","DOI":"10.1148\/rg.220181","volume":"43","author":"FF Guglielmo","year":"2023","unstructured":"Guglielmo FF, Barr RG, Yokoo T et al (2023) Liver fibrosis, fat, and iron evaluation with MRI and fibrosis and fat evaluation with US: a practical guide for radiologists. Radiographics 43:e220181","journal-title":"Radiographics"},{"key":"11533_CR27","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1016\/j.cgh.2017.10.037","volume":"16","author":"C Caussy","year":"2018","unstructured":"Caussy C, Chen J, Alquiraish MH et al (2018) Association between obesity and discordance in fibrosis stage determination by magnetic resonance vs transient elastography in patients with nonalcoholic liver disease. Clin Gastroenterol Hepatol 16:1974\u20131982.e1977","journal-title":"Clin Gastroenterol Hepatol"},{"key":"11533_CR28","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.jhep.2021.04.044","volume":"75","author":"EA Selvaraj","year":"2021","unstructured":"Selvaraj EA, Mozes FE, Jayaswal ANA et al (2021) Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: a systematic review and meta-analysis. J Hepatol 75:770\u2013785","journal-title":"J Hepatol"},{"key":"11533_CR29","doi-asserted-by":"publisher","first-page":"e231092","DOI":"10.1148\/radiol.231092","volume":"309","author":"KJ Fowler","year":"2023","unstructured":"Fowler KJ, Venkatesh SK, Obuchowski N et al (2023) Repeatability of MRI biomarkers in nonalcoholic fatty liver disease: the NIMBLE consortium. Radiology 309:e231092","journal-title":"Radiology"},{"key":"11533_CR30","doi-asserted-by":"publisher","first-page":"e233094","DOI":"10.1148\/radiol.233094","volume":"312","author":"TT Pierce","year":"2024","unstructured":"Pierce TT, Ozturk A, Sherlock SP et al (2024) Reproducibility and repeatability of US shear-wave and transient elastography in nonalcoholic fatty liver disease. Radiology 312:e233094","journal-title":"Radiology"},{"key":"11533_CR31","doi-asserted-by":"publisher","first-page":"e0203054","DOI":"10.1371\/journal.pone.0203054","volume":"13","author":"SA Harrison","year":"2018","unstructured":"Harrison SA, Dennis A, Fiore MM et al (2018) Utility and variability of three non-invasive liver fibrosis imaging modalities to evaluate efficacy of GR-MD-02 in subjects with NASH and bridging fibrosis during a phase-2 randomized clinical trial. PLoS One 13:e0203054","journal-title":"PLoS One"},{"key":"11533_CR32","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/apt.18118","volume":"60","author":"H Siddiqi","year":"2024","unstructured":"Siddiqi H, Huang DQ, Mittal N et al (2024) Repeatability of vibration-controlled transient elastography versus magnetic resonance elastography in patients with cirrhosis: a prospective study. Aliment Pharm Ther 60:484\u2013491","journal-title":"Aliment Pharm Ther"},{"key":"11533_CR33","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1148\/rg.2019190034","volume":"39","author":"FF Guglielmo","year":"2019","unstructured":"Guglielmo FF, Venkatesh SK, Mitchell DG (2019) Liver MR elastography technique and Image Interpretation: Pearls and Pitfalls. Radiographics 39:1983\u20132002","journal-title":"Radiographics"},{"key":"11533_CR34","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1148\/radiol.2016160863","volume":"284","author":"M Wagner","year":"2017","unstructured":"Wagner M, Corcuera-Solano I, Lo G et al (2017) Technical failure of MR elastography examinations of the liver: experience from a large single-center study. Radiology 284:401\u2013412","journal-title":"Radiology"},{"key":"11533_CR35","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1002\/hep.31624","volume":"73","author":"R Loomba","year":"2021","unstructured":"Loomba R (2021) MRI-proton density fat fraction treatment response criteria in nonalcoholic steatohepatitis. Hepatology 73:881\u2013883","journal-title":"Hepatology"},{"key":"11533_CR36","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1016\/j.cgh.2020.08.061","volume":"19","author":"JG Stine","year":"2021","unstructured":"Stine JG, Munaganuru N, Barnard A et al (2021) Change in MRI-PDFF and histologic response in patients with nonalcoholic steatohepatitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 19:2274\u20132283.e2275","journal-title":"Clin Gastroenterol Hepatol"},{"key":"11533_CR37","doi-asserted-by":"publisher","unstructured":"Koh B, Xiao J, Ng CH et al (2024) Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat content: systematic review and network meta-analysis. Hepatology. https:\/\/doi.org\/10.1097\/HEP.0000000000001028","DOI":"10.1097\/HEP.0000000000001028"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-025-11533-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-025-11533-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-025-11533-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:20:47Z","timestamp":1786368047000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-025-11533-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,30]]},"references-count":37,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["11533"],"URL":"https:\/\/doi.org\/10.1007\/s00330-025-11533-0","relation":{},"ISSN":["1432-1084"],"issn-type":[{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,30]]},"assertion":[{"value":"20 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The scientific guarantor of this publication is Dr. Bachir Taouli.","order":1,"name":"Ethics","label":"Guarantor","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"A.M., E.O., S.R., K.M.S, and J.T.D. have no conflicts of interest to declare. M.B.B. has received funding for research from Pfizer, The Kinetix Group, Histoindex, and Siemens. M.B.B. provides consulting services for The Kinetix Group, Madrigal, Pfizer, Fibronostics, NOVO Nordisk, GSK, Boston Pharma, Merck, and Boehringer-Ingelheim. B.T. receives funding for research from Bayer, Takeda, Regeneron, Helio Health, Echosens, Guerbet, and Siemens. Additionally, B.T. provides consulting services for Bayer, Guerbet, and Ascelia.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"One of the authors, John T Doucette, has significant statistical expertise.","order":3,"name":"Ethics","label":"Statistics and biometry","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Written informed consent was waived by the Institutional Review Board.","order":4,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Institutional Review Board approval was obtained.","order":5,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Study subjects or cohorts have not been previously reported.","order":6,"name":"Ethics","label":"Study subjects or cohorts overlap","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"order":7,"name":"Ethics","label":"Methodology","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}}]}}